Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform.
Bayer and UK biotech Bicycle Therapeutics have agreed to collaborate to develop and commercialize the latter’s radioconjugates for multiple oncology targets.
US contract research organization Reaction Biology has acquired German contract laboratory Bioassay Labor für biologische Analytik and its wholly owned subsidiary Peptide Specialty Laboratories (PSL).
Ariceum Therapeutics, a Berlin-headquartered private biotech developing radiopharmaceutical products for the diagnosis and systemic targeted certain hard-to-treat cancers, and AmbioPharm, a globally oriented US CDMO specialized in peptides, have agreed a strategic partnership in peptide conjugates.
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment a few years ago and meanwhile has passed certain milestones on its way to become a preferred oligonucleotide manufacturing partner for pharmaceutical companies.
